NOVOZYMES BIOAG A/S

NOVOZYMES BIOAG A/S has been granted 48 US utility patents between 2015 and 2025, placing NOVOZYMES BIOAG A/S at rank #6,928 across all assignees tracked by PlainPatent. This portfolio spans 17 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.8 claims per patent with primary concentration in A01N (PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS). As a Foreign Corporation, NOVOZYMES BIOAG A/S is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 47.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 24 grants, compared with 24 in the 2015–2019 window — a +0% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. NOVOZYMES BIOAG A/S's 20.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 17 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark NOVOZYMES BIOAG A/S against peers pursuing similar technology classes.